Polymerases & Nucleases Segment Is Projected To Account For A Major Share In The Specialty Enzymes M

By Author: Sonal
Total Articles: 84
Comment this article

The specialty enzymes market was valued at USD 4.4 billion in 2019 and is projected to reach USD 6.6 billion by 2025, recording a CAGR of 6.9% during the forecast period. The demand for enzymes is increasing significantly, as it is being used across various specialty applications and as a substitute for chemical catalysts.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21682828

By type, the specialty enzymes market is segmented into carbohydrases, proteases, lipases, polymerases & nucleases, and other enzymes (such as catalases, laccases, oxidases, phosphatases, kinases, esterases, and pectinases). Polymerases & nucleases have been bolstering the biotechnological advancements for research & developments in the various industries.

They have been used for molecular cloning to manipulate nucleic acids to generate advanced enzymes available today for commercial uses. Polymerases and nucleases have been highly used in the pharmaceutical industry for biotechnological innovations to manufacture various types of drugs. Moreover, their usage bolsters rapid developments ...
... of new diagnostic tests that target DNA and RNA substrates.

Key players in this market include BASF (Germany), Novozymes (Denmark), Roche Holding (Switzerland), DuPont (US), Codexis (US), Dyadic International (US), Advanced Enzymes (India), Amano Enzymes (Japan), Sanofi (France), Biocatalysts (UK), Enzyme Supplies (UK), BBI Solutions (UK), Specialty Enzymes & Probiotics (US), Amicogen (South Korea), Antozyme Biotech (India), Enzyme Development Corporation (US), Nagase & Co. Ltd. (Japan), Sekisui Diagnostics (US), Merck (Germany), and Biovet (Bulgaria).